Impedimed Limited · ASX:IPD
Impedimed — Q4 2025 Earnings Presentation
9 slides from Impedimed's earnings presentation, Jul 30, 2025
Slide 1: Quarterly Activity and Cash Flow Report
ImpediMed Limited Suite 31C, 12-18 Tryon Rd Lindfield NSW 2070 Australia E: investorrelations@impedimed.com W : impedimed.com 31 July 2025 Companies Announcements Office Australian Securities Exchange Quarterly Activity and Cash Flow Report Key highlights for the fouth quarter • Record SOZO® Core Bu
Slide 2: Sales, revenue, ARR and cash flow summary
increase of 22 units (100%) compared with the 22 units sold in Q3 FY25 and an increase of 21 units (91%) compared with the 23 units sold in Q4 FY24. The quality of accounts initiated or renewed in the quarter was pleasing with a significant number being Key Accounts, IDNs, NAPBC and NCCN Centres, co
Slide 3: Reimbursement, new corporate office and management changes
Payments to related parties and their associates during the quarter, disclosed in Section 6 of the Appendix 4C, totalled $93,000 and comprised payments to Non-Executive Directors. Reimbursement A major commercial payor commenced coverage from July 1, 2025, providing a significant increase in depth o
Slide 4: About ImpediMed
About ImpediMed Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform,
Slide 5: Appendix 4C Quarterly cash flow report
Rule 4.7B Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Name of entity ImpediMed Limited ABN Quarter ended (“current quarter”) 65 089 705 144 30 June 2025 Consolidated statement of cash flows Current quarter Year to date $A’000 $A’000 1. Cash flows from operating a
Slide 6: Consolidated statement of cash flows
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Consolidated statement of cash flows Current quarter Year to date $A’000 $A’000 2.2 Proceeds from disposal of: (a) entities - - (b) businesses - - (c) property, plant and equipment - - (d) investments - - (e) intellectu
Slide 7: Consolidated statement of cash flows and reconciliation
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Consolidated statement of cash flows Current quarter Year to date $A’000 $A’000 4.4 Net cash from / (used in) financing activities (713) 13,643 (item 3.10 above) 4.5 Effect of movement in exchange rates on (1,033) (371)
Slide 8: Financing facilities
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B 7. Financing facilities Total facility Amount drawn at Note: the term “facility’ includes all forms of financing amount at quarter quarter end arrangements available to the entity. end $A’000 Add notes as necessary for
Slide 9: Compliance statement
Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Compliance statement 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. 2 This statement gives a true and fair view of the matters disclosed. D